{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-008380","form_type":"8-K","ticker":"ACRS","cik":"0001557746","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2023-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.378723+00:00","generated_at":"2026-06-15T13:12:17.639886+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aclaris posts Q1 net loss of $28.2M; delays PsA and AD trial data timelines","bullets":["Net loss widened to $28.2M from $18.8M YoY; revenue rose to $2.5M on higher licensing royalties.","Cash, cash equivalents and marketable securities $204.4M; ATM raised $26.7M net in April, extending runway through end-2025.","Zunsemetinib RA Phase 2b data guided to Q4 2023; PsA Phase 2a data delayed to H1 2024 (from YE 2023) due to slow European enrollment.","ATI-1777 AD Phase 2b data now expected H2 2023 (from mid-year) after protocol expansion to include milder disease.","ATI-2138 MAD data on track for H2 2023; ulcerative colitis selected as first development target."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-008380","json":"https://secwatch.observer/filing/0001558370-23-008380.json","markdown":"https://secwatch.observer/filing/0001558370-23-008380.md","text":"https://secwatch.observer/filing/0001558370-23-008380.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1557746/000155837023008380/0001558370-23-008380-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1557746/000155837023008380/acrs-20230508x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T13:12:17.639886+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e587a684de001ac6cdf3cdb5343bffb5734278bf","claim":"Aclaris Therapeutics, Inc. reported the first quarter of 2023 results: revenue $2.5 million, net income Net loss was $28.2 million.","evidence_excerpt":"​ Financial Results First Quarter 2023 ● Net loss was $28.2 million for the first quarter of 2023 compared to $18.8 million for the first quarter of 2022. ​ ● Total revenue was $2.5 million for the first quarter of 2023 compared to $1.5 million for the first quarter of 2022. The increase was driven primarily by higher licensing revenues from royalties earned on","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1557746/000155837023008380/0001558370-23-008380-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2023"},{"label":"Revenue","value":"$2.5 million"},{"label":"Net income","value":"Net loss was $28.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}